SCHEMBL4095392

SCHEMBL4095392

CCOC(=O)N1CCN(c2nc(-c3ccc(Cl)cc3Cl)nc3ccccc23)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.63
KMT2A Q03164 8/20 0.63
ABCB1 P08183 1/20 0.53
GBA1 P04062 4/20 0.50
IDE P14735 1/20 0.50
MAPT P10636 3/20 0.49
ABCG2 Q9UNQ0 1/20 0.48
HSD17B10 Q99714 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 2/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 2/20 0.47
CYP2C9 P11712 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095953 0.90 MEN1 (0.67) MEN1KMT2AABCB1GBA1MAPT
SCHEMBL4090724 0.89 KMT2A (0.55) MEN1KMT2AABCB1GBA1IDE
SCHEMBL4091440 0.89 KMT2A (0.55) MEN1KMT2AABCB1IDEMAPT
SCHEMBL4091214 0.87 GBA1 (0.60) MEN1KMT2AABCB1GBA1MAPT
SCHEMBL4096171 0.86 MEN1 (0.67) MEN1KMT2AGBA1MAPTABCG2
SCHEMBL4095415 0.84 KMT2A (0.57) MEN1KMT2AABCB1GBA1IDE
SCHEMBL4090537 0.83 MEN1 (0.63) MEN1KMT2AABCB1GBA1MAPT
SCHEMBL4084978 0.83 MAPT (0.57) MEN1KMT2AIDEMAPTHSD17B10
SCHEMBL4095069 0.83 MEN1 (0.63) MEN1KMT2AGBA1MAPTHSD17B10
SCHEMBL1084085 0.82 MEN1 (0.67) MEN1KMT2AGBA1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MEN1 718/4885KMT2A 1424/4885ABCB1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.